Eubicarbonatemic Hydrogen Ion Retention and CKD Progression

Small-scale trials in patients with chronic kidney disease (CKD) 3-5 have shown that hypobicarbonatemic metabolic acidosis promotes progression of CKD. Accordingly, the 2012 KDIGO (Kidney Disease: Improving Global Outcomes) guideline suggests base administration to patients with CKD when serum bicar...

Descripción completa

Detalles Bibliográficos
Autor principal: Madias, Nicolaos E.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2021
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8350821/
https://www.ncbi.nlm.nih.gov/pubmed/34401727
http://dx.doi.org/10.1016/j.xkme.2021.03.012

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8350821/
https://www.ncbi.nlm.nih.gov/pubmed/34401727
http://dx.doi.org/10.1016/j.xkme.2021.03.012

Ejemplares similares